EG Capital Group

Presto is a technology company that specializes in providing advanced digital solutions to the hospitality industry, particularly in automating operations for drive-thrus. Founded at M.I.T. in 2008 and headquartered in Silicon Valley, California, Presto leverages voice, vision, and touch technologies to enhance guest experiences and help businesses address labor shortages. The company has shipped over 250,000 systems, making it one of the largest providers of labor automation technology in its sector. Its customer base includes many of the top 20 restaurant chains in the United States, where Presto's solutions contribute to generating new revenue and streamlining operations.

C4 Therapeutics, Inc. is a biopharmaceutical company focused on developing innovative therapeutic candidates that target and eliminate disease-causing proteins, primarily for the treatment of cancer and neurodegenerative disorders. The company's lead product candidate, CFT7455, is an orally bioavailable degrader designed to target IKZF1/3 for multiple myeloma and other lymphomas. Additionally, C4 is advancing CFT8634, which targets BRD9 for specific solid tumors, alongside programs aimed at genetically defined resistant solid tumors. C4 Therapeutics utilizes its proprietary Degronimid platform, which allows for the selective degradation of proteins through the natural ubiquitin/proteasome system, potentially addressing previously undruggable targets while minimizing drug resistance. The company has formed strategic collaborations with major industry players, and it aims to make a significant impact on the treatment landscape through its advanced protein degradation science and multiple development programs. Founded in 2015 and headquartered in Watertown, Massachusetts, C4 Therapeutics continues to innovate in the field of targeted therapy.